title: [Is syndecan-1 an independent prognostic factor in patients with laryngeal carcinoma?].
abstract: Syndecan-1 is a member of the syndecan family of cell membrane heparan sulphate proteoglicans. The aim of this study was the evaluation of prognostic value of syndecan-1 expression in laryngeal cancer. The findings were correlated with the clinico-pathological parameters of the tumours, as well as with patient survival rate. Paraffin-embedded samples from 99 patients with laryngeal cancer selected from the files of the ENT-Dept. of Medical Academy in Lublin were immunostained with anti-syndecan-1 monoclonal antibody. The patients' mean age was 57 years and the over 5-year survival rate was 53.2%. Syndecan-1 immunoreactivity was observed in 99 (100%) of carcinomas. In our study, a statisti- cally significant correlation between syndecan-1 expression and patient survival rate was observed (chi2 = 9631; p = 0.008) as well as between syndecan-1 expression and various clinical stages of disease (chi2 = 6771; p = 0.034). The significant difference in the presence of syndecan-1 expression among the patients with various stage of histological differentiation of carcinoma (chi2 = 14.9; p = 0.001), and among the patients with present and absent metastatic changes in regional lymph nodes (chi2 = 16.698; p = 0.001) was observed. In a Coxs multivariate analysis syndecan-1 had an independent prognostic value (p = 0.014). Our results indicate that syndecan-1 could be used as a prognostic marker in laryngeal cancer.
authors.affiliation: Klinika Otolaryngologii AM, Lublinie.
authors.forename: Janusz
authors.initials: J
authors.lastname: Klatka
authors.forename: Danuta
authors.initials: D
authors.lastname: Skomra
authors.forename: Roman
authors.initials: R
authors.lastname: Paduch
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Kupisz
authors.forename: Elzbieta
authors.initials: E
authors.lastname: Tryka
authors.forename: Mcłgorzata
authors.initials: M
authors.lastname: Harytanowicz
authors.forename: Adam
authors.initials: A
authors.lastname: Kłos
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000276:immunology; D002277:Carcinoma / Q000276:immunology / Q000378:metabolism* / Q000401:mortality; D006801:Humans; D007150:Immunohistochemistry; D007822:Laryngeal Neoplasms / Q000276:immunology / Q000378:metabolism* / Q000401:mortality; D008562:Membrane Glycoproteins / Q000276:immunology / Q000378:metabolism*; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D011509:Proteoglycans / Q000276:immunology / Q000378:metabolism*; D015996:Survival Rate; D053668:Syndecan-1; D053667:Syndecans
chemical_list: D000911:Antibodies, Monoclonal; D008562:Membrane Glycoproteins; D011509:Proteoglycans; C508241:SDC1 protein, human; D053668:Syndecan-1; D053667:Syndecans